Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01320943
Other study ID # GS-EU-174-0160
Secondary ID 2010-021925-12
Status Completed
Phase Phase 4
First received March 9, 2011
Last updated August 29, 2016
Start date April 2011
Est. completion date August 2016

Study information

Verified date August 2016
Source Gilead Sciences
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

Withdrawal of antiviral therapy can result in hepatic or alanine aminotransferase (ALT) flares as Hepatitis B Virus (HBV) replication resumes; however, in some participants, a flare exacerbates chronic hepatitis temporarily but can also result in viral clearance. Hepatic flares are common after stopping anti-HBV therapy.

Only participants who already are on treatment with tenofovir disoproxil fumarate (TDF) monotherapy or TDF in combination with lamivudine or emtricitabine for at least 4 years and who achieved and maintained virologic suppression (< 400 copies/mL) for 3.5 or more years will be included in this study. One treatment arm will stop the TDF therapy while the other treatment arm will continue the TDF therapy.

Participants in the Stop TDF arm will be monitored very closely with special focus on biochemical flares (especially ALT increases) and virological relapses (Hepatitis B viral load increases). If any participant in the Stop TDF arm exceeds one or more predefined limits for such flares or relapses, TDF will be reinstituted.

The study will assess Hepatitis B surface antigen (HBsAg) loss (i.e. specific Hepatitis B virus components are no longer detectable) and seroconversion (occurrence of Hepatitis B surface antibody, a specific antibody which usually occurs after HBsAg loss) rates during study duration. The percentage of participants who need to restart TDF therapy in the Stop TDF arm will also be evaluated.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date August 2016
Est. primary completion date July 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Chronic hepatitis B, hepatitis B e-antigen negative, hepatitis B e-antibody positive, and hepatitis B surface antigen-positive

- Hepatitis B e Antigen (HBeAg)-negative at the beginning of TDF therapy (i.e. TDF monotherapy or combination of TDF + lamivudine or TDF + emtricitabine)

- Received continuous TDF therapy (i.e. TDF monotherapy or combination of TDF + lamivudine or TDF + emtricitabine) treatment for at least 4 years prior to screening. If TDF has been used in combination with lamivudine or emtricitabine, lamivudine or emtricitabine must have been stopped at least 12 weeks prior to screening

- Documented hepatitis B virus DNA (HBV DNA) < 400 copies/mL for at least 3.5 years prior to screening and at screening

- ALT within normal range

- a-fetoprotein (AFP) <= 50 ng/mL

- Calculated creatinine clearance >= 70 mL/min by Cockcroft-Gault formula using ideal body weight

- <= 10 kPa on Fibroscan assessment

- A negative serum pregnancy test for female subjects

- Adult subjects >= 18 years of age

Exclusion Criteria:

- Known cirrhosis

- Evidence of fibrosis >= Stage 3 (METAVIR) on liver biopsy or Fibroscan > 10 kPa within 6 months prior to screening

- Documentation of confirmed episodes (i.e., 2 consecutive values) of HBV DNA > 400 copies/mL within 3.5 years prior to screening

- History of decompensated liver disease (defined as direct [conjugated] bilirubin > 1.5 x upper limit of normal, prothrombin time (PT) > 1.5 x upper limit of normal, platelets < 75,000/mm³, serum albumin < 3.0 g/dL

- History of clinical hepatic decompensation in the judgement of the investigator

- Evidence of hepatocellular carcinoma

- Significant bone disease (in the judgment of the investigator)

- Serological evidence of coinfection with human immunodeficiency virus (HIV), hepatitis C virus, or hepatitis D infection

- Known hypersensitivity to TDF, its metabolites, or formulation excipients

- Concomitant therapy with disallowed medications

- History of malignant disease

- Lactating females

- Females wishing to became pregnant during the duration of the stud

- Subjects participating in another clinical trial can only be enrolled at the discretion of the Medical Monitor

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
TDF
Tenofovir disoproxil fumarate (TDF) 300 mg tablet administered orally once daily
Other:
Stop TDF
Participants will stop TDF therapy

Locations

Country Name City State
Germany Charite CVK Berlin
Germany Leberzentrum am Checkpoint Berlin
Germany Zentrum für HIV und Hepatitis Duesseldorf
Germany J.W. Goethe Universitaetsklinikum Frankfurt
Germany ifi Studien und Projekte GmbH Hamburg
Germany Universitaetsklinikum Hamburg Eppendorf Hamburg
Germany Medizinische Hochschule Hannover Hannover
Germany Universitaetsklinik Heidelberg Heidelberg
Germany Gastroenterologische Gemeinschaftspraxis Herne
Germany Universitaetsklinikum Leipzig Leipzig
Germany Gemeinschaftspraxis Gastroenterologie Leverkusen
Germany Klinikum der LMU Grosshadern Muenchen
Germany Universitaetsklinikum Ulm Ulm

Sponsors (1)

Lead Sponsor Collaborator
Gilead Sciences

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of participants with HBsAg loss at Week 144 in both study arms The proportion of participants with HBsAg loss will be evaluated using the Kaplan-Meier (KM) product limit method. Participants who have not experienced HBsAg loss but discontinue from the study prior to Week 144 are considered censored at the last HBsAg collection date. Log-rank test statistic will be used to compare the time to HBsAg loss between the two treatment arms. Week 144 No
Secondary Proportion of participants with seroconversion in both study arms The proportion of participants with seroconversion at Weeks 96 and 144 and will be summarized. Weeks 96 and 144 No
Secondary Change from baseline in quantitative HBsAg (IU/mL) in both study arms Baseline to Week 144 No
Secondary Proportion of participants who restart TDF therapy in the Stop TDF arm The proportion of participants who restart TDF therapy in Stop TDF arm at Weeks 48, 96 and 144 will be estimated using the Kaplan-Meier (KM) product limit method. Participants who have not re-started TDF therapy but discontinue from the study will be considered as censored at the last laboratory collection date. Weeks 48, 96, and 144 No
Secondary Proportion of participants with viral suppression in the Stop TDF arm Viral suppression is defined as not having two consecutive HBV DNA = 400 copies/mL. Baseline to Week 144 No
Secondary Proportion of participants with ALT < upper limit of the normal range in the Stop TDF arm Baseline to Week 144 No
Secondary Proportion of participants with HBsAg loss at Week 96 in both study arms Week 96 No
See also
  Status Clinical Trial Phase
Recruiting NCT04496882 - Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue Phase 4
Completed NCT04083716 - A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults Phase 1
Not yet recruiting NCT03038802 - A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Phase 1/Phase 2
Completed NCT05310487 - Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects Phase 1
Recruiting NCT06070051 - Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy Phase 1
Terminated NCT05001022 - A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects Phase 1
Recruiting NCT04139850 - The Establishment of Korean Hepatitis B Patients Cohort
Recruiting NCT05343481 - Efficacy of VTP-300 in Chronic Hepatitis B Infection Phase 2
Not yet recruiting NCT05490836 - Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients N/A
Recruiting NCT04543565 - Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study Phase 3
Active, not recruiting NCT02894918 - A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs Phase 4
Not yet recruiting NCT02793791 - Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients N/A
Recruiting NCT02287857 - Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B N/A
Recruiting NCT01965418 - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Phase 4
Recruiting NCT01491295 - Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Phase 4
Terminated NCT01872988 - Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma Phase 3
Recruiting NCT01487876 - Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients Phase 2
Not yet recruiting NCT01436539 - Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Phase 4
Completed NCT01531166 - A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon N/A
Recruiting NCT01360879 - Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease N/A